# 2026-20442: Nerve Gas Antidote Autoinjector Gets Green Light for Cheap Generics

2026-20442, Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-10-06; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20442
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20442
- Title: Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63562
- Published: 2026-10-06
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

Nerve Gas Antidote Autoinjector Gets Green Light for Cheap Generics

## Summary

The FDA has confirmed that the Pralidoxime Chloride autoinjector was not taken off the market because of safety or effectiveness problems. This means generic versions can now be approved, making it easier and potentially cheaper for people who need this medicine. Patients, healthcare providers, and drug makers can expect more options soon without any safety worries.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) has determined that PRALIDOXIME CHLORIDE (AUTOINJECTOR) (pralidoxime chloride) solution, 600 milligrams (mg)/2 milliliters (mL) (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for pralidoxime chloride solution, 600 mg/2 mL (300 mg/mL), if all other legal and regulatory requirements are met.

## Effects PRIA read

- Generic Pralidoxime Autoinjector Approvals Allowed: benefit, low. FDA determined that PRALIDOXIME CHLORIDE (AUTOINJECTOR) solution, 600 mg/2 mL (300 mg/mL), was not withdrawn for reasons of safety or effectiveness. Because of that finding, the Agency said it may approve abbreviated new drug applications (ANDAs) for this product if the applicants meet all other le…
- No Safety/Effectiveness Withdrawal Found: benefit, low. FDA reviewed its records, literature, and postmarketing adverse event data and found no information showing that PRALIDOXIME CHLORIDE (AUTOINJECTOR), 600 mg/2 mL (300 mg/mL), was withdrawn from sale for reasons of safety or effectiveness. The product (NDA 018986, initially approved April 26, 1983)…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20442 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20442/determination-pralidoxime-chloride-autoinjector-pralidoxime-chloride-solution-600-milligrams2)
- [2026-20442 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20442.pdf)

## Related
- [Previous: 2026-20438, Privacy Act of 1974; Systems of Records](https://policyrisk.com/federal-register/2026-20438)
- [Next: 2026-20446, Agency Information Collection Activities Under OMB Review](https://policyrisk.com/federal-register/2026-20446)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20442 (as of 2026-10-13).
